These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4 Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S J Virol; 2018 May; 92(9):. PubMed ID: 29444937 [TBL] [Abstract][Full Text] [Related]
6. The role of latency reversal agents in the cure of HIV: A review of current data. Bashiri K; Rezaei N; Nasi M; Cossarizza A Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743 [TBL] [Abstract][Full Text] [Related]
7. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214 [TBL] [Abstract][Full Text] [Related]
8. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure. Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication. Dhamija N; Rawat P; Mitra D Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264 [TBL] [Abstract][Full Text] [Related]
17. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption. Wang X; Xu H Viruses; 2021 Feb; 13(2):. PubMed ID: 33670027 [TBL] [Abstract][Full Text] [Related]
18. Current views on HIV-1 latency, persistence, and cure. Melkova Z; Shankaran P; Madlenakova M; Bodor J Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447 [TBL] [Abstract][Full Text] [Related]
19. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs. Darcis G; Berkhout B; Pasternak AO Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381 [TBL] [Abstract][Full Text] [Related]
20. Therapeutics for HIV-1 reactivation from latency. Sgarbanti M; Battistini A Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]